Tags

Type your tag names separated by a space and hit enter

High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Int Clin Psychopharmacol. 2008 Jan; 23(1):49-53.IC

Abstract

The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD). In an open-label, 16-week prospective study, patients with OCD received escitalopram at a dose of 20 mg/day for 3 weeks, after a 1-week titration at 10 mg/day. Patients who did not achieve a > or =25% reduction from baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score during these 4 weeks were continued on higher doses of escitalopram (maximum 50 mg/day) for 12 weeks. The primary efficacy measure of OCD symptoms was change from baseline in the Y-BOCS score. Overall, 67 patients (33 women, 34 men) with a mean Y-BOCS score of 29.6 entered the study. After 4 weeks of standard-dose escitalopram treatment, one patient discontinued owing to pregnancy, and two patients achieved a reduction in Y-BOCS > or =25%. Consequently, 64 patients were eligible to receive high-dose escitalopram (mean dose, 33.8 mg/day at endpoint). At endpoint, high-dose escitalopram had significantly improved the OCD symptoms (Y-BOCS score) and all the other efficacy measures (P<0.001), compared with baseline. Escitalopram was also well tolerated, with no discontinuations during the 12-week high-dose phase. The only reported adverse drug reactions were dry mouth (n=8, 12.1%) and decreased sexual desire (n=21, 31.8%). Preliminary investigation shows that high-dose escitalopram is an efficacious and well tolerated treatment for patients suffering from severe OCD. Randomized, blinded studies are needed to reinforce these findings.

Authors+Show Affiliations

The YOTAM Treatment Center, Ramat-Gan bAbarbanel Mental Health Center, Bat-Yam, Israel.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18090508

Citation

Rabinowitz, Ilan, et al. "High-dose Escitalopram for the Treatment of Obsessive-compulsive Disorder." International Clinical Psychopharmacology, vol. 23, no. 1, 2008, pp. 49-53.
Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23(1):49-53.
Rabinowitz, I., Baruch, Y., & Barak, Y. (2008). High-dose escitalopram for the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology, 23(1), 49-53.
Rabinowitz I, Baruch Y, Barak Y. High-dose Escitalopram for the Treatment of Obsessive-compulsive Disorder. Int Clin Psychopharmacol. 2008;23(1):49-53. PubMed PMID: 18090508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-dose escitalopram for the treatment of obsessive-compulsive disorder. AU - Rabinowitz,Ilan, AU - Baruch,Yehuda, AU - Barak,Yoram, PY - 2007/12/20/pubmed PY - 2008/2/15/medline PY - 2007/12/20/entrez SP - 49 EP - 53 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 23 IS - 1 N2 - The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD). In an open-label, 16-week prospective study, patients with OCD received escitalopram at a dose of 20 mg/day for 3 weeks, after a 1-week titration at 10 mg/day. Patients who did not achieve a > or =25% reduction from baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score during these 4 weeks were continued on higher doses of escitalopram (maximum 50 mg/day) for 12 weeks. The primary efficacy measure of OCD symptoms was change from baseline in the Y-BOCS score. Overall, 67 patients (33 women, 34 men) with a mean Y-BOCS score of 29.6 entered the study. After 4 weeks of standard-dose escitalopram treatment, one patient discontinued owing to pregnancy, and two patients achieved a reduction in Y-BOCS > or =25%. Consequently, 64 patients were eligible to receive high-dose escitalopram (mean dose, 33.8 mg/day at endpoint). At endpoint, high-dose escitalopram had significantly improved the OCD symptoms (Y-BOCS score) and all the other efficacy measures (P<0.001), compared with baseline. Escitalopram was also well tolerated, with no discontinuations during the 12-week high-dose phase. The only reported adverse drug reactions were dry mouth (n=8, 12.1%) and decreased sexual desire (n=21, 31.8%). Preliminary investigation shows that high-dose escitalopram is an efficacious and well tolerated treatment for patients suffering from severe OCD. Randomized, blinded studies are needed to reinforce these findings. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/18090508/High_dose_escitalopram_for_the_treatment_of_obsessive_compulsive_disorder_ L2 - https://doi.org/10.1097/YIC.0b013e3282f0f0c5 DB - PRIME DP - Unbound Medicine ER -